FDA Requests Data from Clovis for Rociletinib NDA in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has requested additional clinical data from Clovis Oncology Inc., for the agency’s efficacy analysis of the 500mg and 625mg BID dose patient groups for rociletinib. Clovis said it would provide the information in a major amendment to the FDA.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login